Germany-based biotech Artes and Bio Farma, based in Indonesia, have joined to develop and manufacture vaccine candidates. The collaboration involves Artes’ specialization in cell line and process development, VLP-based vaccines and technology transfer for production processes, and Bio Farma’s experience manufacturing vaccines for the Indonesian domestic and international markets.

“Bio Farma is the only vaccine and antisera producer in Indonesia. We expect that developments based on Metavax technology will contribute to Bio Farma´s vaccine portfolio,” said Dr. Michael Piontek, founder and managing director of Artes. Artes´ Metavax is a VLP technology based on modifications to the hepatitis B virus.